Airflow limitation in people living with HIV and matched uninfected controls
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Airflow limitation in people living with HIV and matched uninfected controls. / Ronit, Andreas; Lundgren, Jens; Afzal, Shoaib; Benfield, Thomas; Roen, Ashley; Mocroft, Amanda; Gerstoft, Jan; Nordestgaard, Børge G; Vestbo, Jørgen; Nielsen, Susanne D; Copenhagen Co-morbidity in HIV infection (COCOMO) study group.
In: Thorax, Vol. 73, No. 5, 2018, p. 431-438.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Airflow limitation in people living with HIV and matched uninfected controls
AU - Ronit, Andreas
AU - Lundgren, Jens
AU - Afzal, Shoaib
AU - Benfield, Thomas
AU - Roen, Ashley
AU - Mocroft, Amanda
AU - Gerstoft, Jan
AU - Nordestgaard, Børge G
AU - Vestbo, Jørgen
AU - Nielsen, Susanne D
AU - Copenhagen Co-morbidity in HIV infection (COCOMO) study group
N1 - © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
PY - 2018
Y1 - 2018
N2 - INTRODUCTION: Whether HIV influences pulmonary function remains controversial. We assessed dynamic pulmonary function in people living with HIV (PLWHIV) and uninfected controls.METHODS: A total of 1098 PLWHIV from the Copenhagen Co-morbidity in HIV infection study and 12 161 age-matched and sex-matched controls from the Copenhagen General Population Study were included. Lung function was assessed using FEV1 and FVC, while airflow limitation was defined by the lower limit of normal (LLN) of FEV1/FVC and by FEV1/FVC<0.7 with FEV1predicted <80% (fixed). Logistic and linear regression models were used to determine the association between HIV and pulmonary function adjusting for potential confounders (including smoking and socioeconomic status).RESULTS: In predominantly white men with mean (SD) age of 50.6 (11.1) the prevalence of airflow limitation (LLN) was 10.6% (95% CI 8.9% to 12.6%) in PLWHIV and 10.6% (95% CI 10.0 to 11.1) in uninfected controls. The multivariable adjusted OR for airflow limitation defined by LLN for HIV was 0.97 (0.77-1.21, P<0.78) and 1.71 (1.34-2.16, P<0.0001) when defined by the fixed criteria. We found no evidence of interaction between HIV and cumulative smoking in these models (P interaction: 0.25 and 0.17 for LLN and fixed criteria, respectively). HIV was independently associated with 197 mL (152-242, P<0.0001) lower FEV1 and 395 mL (344-447, P<0.0001) lower FVC, and 100 cells/mm3 lower CD4 nadir was associated with 30 mL (7-52, P<0.01) lower FEV1 and 51 mL (24-78, P<0.001) lower FVC.CONCLUSION: HIV is a risk factor for concurrently decreased FEV1 and FVC. This excess risk is not explained by smoking or socioeconomic status and may be mediated by prior immunodeficiency.TRIAL REGISTRATION NUMBER: NCT02382822.
AB - INTRODUCTION: Whether HIV influences pulmonary function remains controversial. We assessed dynamic pulmonary function in people living with HIV (PLWHIV) and uninfected controls.METHODS: A total of 1098 PLWHIV from the Copenhagen Co-morbidity in HIV infection study and 12 161 age-matched and sex-matched controls from the Copenhagen General Population Study were included. Lung function was assessed using FEV1 and FVC, while airflow limitation was defined by the lower limit of normal (LLN) of FEV1/FVC and by FEV1/FVC<0.7 with FEV1predicted <80% (fixed). Logistic and linear regression models were used to determine the association between HIV and pulmonary function adjusting for potential confounders (including smoking and socioeconomic status).RESULTS: In predominantly white men with mean (SD) age of 50.6 (11.1) the prevalence of airflow limitation (LLN) was 10.6% (95% CI 8.9% to 12.6%) in PLWHIV and 10.6% (95% CI 10.0 to 11.1) in uninfected controls. The multivariable adjusted OR for airflow limitation defined by LLN for HIV was 0.97 (0.77-1.21, P<0.78) and 1.71 (1.34-2.16, P<0.0001) when defined by the fixed criteria. We found no evidence of interaction between HIV and cumulative smoking in these models (P interaction: 0.25 and 0.17 for LLN and fixed criteria, respectively). HIV was independently associated with 197 mL (152-242, P<0.0001) lower FEV1 and 395 mL (344-447, P<0.0001) lower FVC, and 100 cells/mm3 lower CD4 nadir was associated with 30 mL (7-52, P<0.01) lower FEV1 and 51 mL (24-78, P<0.001) lower FVC.CONCLUSION: HIV is a risk factor for concurrently decreased FEV1 and FVC. This excess risk is not explained by smoking or socioeconomic status and may be mediated by prior immunodeficiency.TRIAL REGISTRATION NUMBER: NCT02382822.
KW - Adult
KW - CD4 Lymphocyte Count
KW - Case-Control Studies
KW - Female
KW - Forced Expiratory Volume
KW - HIV Infections/blood
KW - Humans
KW - Male
KW - Middle Aged
KW - Prospective Studies
KW - Risk Factors
KW - Tobacco Smoking/physiopathology
KW - Vital Capacity
U2 - 10.1136/thoraxjnl-2017-211079
DO - 10.1136/thoraxjnl-2017-211079
M3 - Journal article
C2 - 29331988
VL - 73
SP - 431
EP - 438
JO - Thorax
JF - Thorax
SN - 0040-6376
IS - 5
ER -
ID: 215788513